SamJosephLubnerMDFACP

Oncology • Madison, WI

Gastrointestinal Cancer

Fellowship Director Associate Professor of Medicine, University of Wisconsin School of Medicine and Public Health

Join to view full profile

Dr. Lubner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lubner's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2008 - 2010
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
University of Wisconsin School of Medicine & Public HealthClass of 2003

Certifications & Licensure

WI State Medical License 2008 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

84 citations
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Vaibhav Sahai, Paul J. Catalano, Mark M. Zalupski, Sam J. Lubner, Mark R. Menge
JAMA Oncology. 2018-12-01
515 citations
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam J. Lubner
The Lancet. Oncology. 2020-06-01
206 citations
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X. Zhu, Teresa Macarulla, Milind Javle, R. Kate Kelley, Sam J. Lubner
JAMA Oncology. 2021-11-01

Press Mentions

Health Care Professionals Remind People to Be Screened for Colon CancerMarch 8th, 2023
UW Medical School Students Receive Residency Placement on Match DayMarch 23rd, 2021
Impact of COVID-19 Pandemic on Cancer Diagnosis—When Fewer Cases of Cancer Is Not Good NewsMarch 21st, 2021
Join now to see all